April 2nd, 2018 | Highly Respected Orlando Cancer Doctor to Become Medical Director Diverse Biotech is extremely pleased to announce the execution of a Medical Director Agreement withDr. Sarah Katta of Southwest Cancer Center in Orlando Florida. Since insurance doesn’t cover cannabinoids, oncology patients who are less fortunate and under Southwest Cancer Centers care may […]
Read More
Diverse Biotech to Focus in FDA Clinical trial ORLANDO, FL | June 4th, 2018 Diverse Biotech Inc., is a private biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it is pursuing preclinical studies of a pipeline compound BRCX014 in adult patients with Glioblastoma. BRCX014 is also […]
Read More
Patents have been filed with the United States Patent and Trademark Office for 14 different areas. An update on this release are forthcoming.
Read More
Glioblastoma – from Diagnosis to Treatment and Clinical Trials Tumors that occur in the brain without a known origin are called gliomas. The most malignant forms are glioblastomas. Glioblastoma is an aggressive, infiltrative type of cancer that can strike in the brain or spinal cord. Glioblastoma forms from star-shaped glial cells of the central nervous […]
Read More

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases

Tag Cloud